A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT

Am J Hematol. 2002 Sep;71(1):37-40. doi: 10.1002/ajh.10166.

Abstract

A 26-year-old male with acute lymphoblastic leukemia (ALL) in its second complete remission received an unrelated bone marrow transplantation (UBMT) following cyclophosphamide plus total body irradiation conditioning. The patient relapsed 7 months after the BMT. He received a second UBMT from a different donor 15 months after the initial UBMT. Conditioning for the second UBMT consisted of busulphan, melphalan, and anti-thymocyte globulin. The regimen was well tolerated, and engraftment was achieved. Both acute and chronic graft-versus-host diseases occurred but were successfully controlled with immunosuppressive drugs. He is alive and disease-free 29 months after the second UBMT. This is the first report of a successful second UBMT for ALL that had relapsed after the first UBMT and for which a different donor was used.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / administration & dosage
  • Azathioprine / therapeutic use
  • Bone Marrow Transplantation* / adverse effects
  • Cyclophosphamide / administration & dosage
  • Daunorubicin / administration & dosage
  • Drug Therapy, Combination
  • Female
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / etiology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Living Donors*
  • Male
  • Methotrexate / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use
  • Recurrence
  • Remission Induction
  • Tacrolimus / therapeutic use
  • Transplantation Conditioning
  • Transplantation, Homologous* / adverse effects
  • Vincristine / administration & dosage

Substances

  • Immunosuppressive Agents
  • Vincristine
  • Cyclophosphamide
  • Prednisolone
  • Asparaginase
  • Azathioprine
  • Tacrolimus
  • Methotrexate
  • Daunorubicin